BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou WX, Chen C, Liu XQ, Li Y, Lin YL, Wu XT, Kong LY, Luo JG. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem 2021;210:112980. [PMID: 33176943 DOI: 10.1016/j.ejmech.2020.112980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou WX, Chen C, Liu XQ, Li Y, Kong LY, Luo JG. Synthesis and biological evaluation of novel withangulatin A derivatives as potential anticancer agents. Bioorg Chem 2021;108:104690. [PMID: 33592485 DOI: 10.1016/j.bioorg.2021.104690] [Reference Citation Analysis]
2 Subramani R, Poudel S, Smith KD, Estrada A, Lakshmanaswamy R. Metabolomics of Breast Cancer: A Review. Metabolites 2022;12:643. [DOI: 10.3390/metabo12070643] [Reference Citation Analysis]
3 Gandhi A, Masand V, Zaki MEA, Al-Hussain SA, Ghorbal AB, Chapolikar A. Quantitative Structure-Activity Relationship Evaluation of MDA-MB-231 Cell Anti-Proliferative Leads. Molecules 2021;26:4795. [PMID: 34443383 DOI: 10.3390/molecules26164795] [Reference Citation Analysis]
4 Carbone D, Vestuto V, Ferraro MR, Ciaglia T, Pecoraro C, Sommella E, Cascioferro S, Salviati E, Novi S, Tecce MF, Amodio G, Iraci N, Cirrincione G, Campiglia P, Diana P, Bertamino A, Parrino B, Ostacolo C. Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]